FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Véronique Joly

Research Profile

Disorders

Chemicals & Drugs

Procedures

Living Beings

Physiology

Viral Drug Resistance

Concepts & Ideas

Viral Load

Co-author Network

Publications

TOP 3
Véronique Joly; François Raffi; Sophie Tabuteau; Yazdan Yazdanpanah; Patrick Yeni; André Cabie; Charlotte Charpentier; Geneviève Chene; Nathalie Colin de Verdiere; Diane Descamps; Catherine Fagard; Carine Grondin
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Matthieu Groh; Sandrine Houze; Véronique Joly; Stéphane Simon; Isabelle Villena; Daniel Ajzenberg; Dominique Aubert; Bernard Carme; Cécile Charlois-Ou; Magalie Demar; Alexandra Faussart; Patrick Yeni
Acute lung, heart, liver, and pancreatic involvements with hyponatremia and retinochoroiditis in a 33-year-old French Guianan patient.
Véronique Joly; Kaoutar Jidar; Mercedes Tatay; Patrick Yeni
Enfuvirtide: from basic investigations to current clinical use.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Véronique Joly (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Véronique Joly; François Raffi; Sophie Tabuteau; Yazdan Yazdanpanah; Patrick Yeni; André Cabie; Charlotte Charpentier; Geneviève Chene; Nathalie Colin de Verdiere; Diane Descamps; Catherine Fagard; Carine Grondin
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Antimicrobial agents and chemotherapy 2013;57(2):758-65.
2012: Matthieu Groh; Sandrine Houze; Véronique Joly; Stéphane Simon; Isabelle Villena; Daniel Ajzenberg; Dominique Aubert; Bernard Carme; Cécile Charlois-Ou; Magalie Demar; Alexandra Faussart; Patrick Yeni
Acute lung, heart, liver, and pancreatic involvements with hyponatremia and retinochoroiditis in a 33-year-old French Guianan patient.
PLoS neglected tropical diseases 2012;6(10):e1802.
2010: Véronique Joly; Kaoutar Jidar; Mercedes Tatay; Patrick Yeni
Enfuvirtide: from basic investigations to current clinical use.
Expert opinion on pharmacotherapy 2010;11(16):2701-13.
2008: Agnès Meybeck; Claude Fortin; raymond ruimy; Véronique Joly; Patrick Yeni
Active tuberculosis does not always imply the initiation of highly active antiretroviral therapy in HIV-infected patients.
Journal of acquired immune deficiency syndromes (1999) 2008;47(2):259-61.
2007: Agnès Meybeck; J Calbet; raymond ruimy; K Mashri; M Jachym; Véronique Joly; Patrick Yeni
Multidrug-resistant tuberculous meningitis in an HIV-positive patient: a challenging disease.
AIDS patient care and STDs 2007;21(3):149-53.
2006: Claude Fortin; Véronique Joly; Patrick Yeni
Emerging reverse transcriptase inhibitors for the treatment of HIV infection in adults.
Expert opinion on emerging drugs 2006;11(2):217-30.
2005: Diane Descamps; Véronique Joly; Philippe Flandre; Gilles Peytavin; Vincent Meiffrédy; Séverine Delarue; STEPHANE LASTERE; Jean-Pierre Aboulker; Patrick Yeni; Françoise Brun-Vézinet
Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2005;33(2):99-103.
2005: Véronique Joly; Patrick Yeni
Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Antiviral therapy 2005;10(1):29-40.
2005: Denise Lecossier; Nancy S Shulman; Laurence Morand-Joubert; Robert W Shafer; Véronique Joly; Andrew R Zolopa; François Clavel; Allan J Hance
Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine.
Journal of acquired immune deficiency syndromes (1999) 2005;38(1):37-42.
2004: Claude Fortin; Véronique Joly
Efavirenz for HIV-1 infection in adults: an overview.
Expert review of anti-infective therapy 2004;2(5):671-84.
2004: Philippe Flandre; Alexandre Alcais; Diane Descamps; Laurence Morand-Joubert; Véronique Joly
Estimating and comparing reduction in HIV-1 RNA in clinical trials using methods for interval censored data.
Journal of acquired immune deficiency syndromes (1999) 2004;35(3):286-92.
2004: Philippe Flandre; Diane Descamps; Véronique Joly; Vincent Meiffredy; Catherine Tamalet; Jacques Izopet; Françoise Brun Vezinet
A survival method to estimate the time to occurrence of mutations: an application to thymidine analogue mutations in HIV-1-infected patients.
The Journal of infectious diseases 2004;189(5):862-70.
2004: Véronique Joly; Diane Descamps; Gilles Peytavin; Fatiha Touati; France Mentre; Xavier Duval; Séverine Delarue; Patrick Yeni; Françoise Brun Vezinet
Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.
Antimicrobial agents and chemotherapy 2004;48(1):172-5.
2003: Sophie Abgrall; Xavier Duval; Véronique Joly; Diane Descamps; Sophie Matheron; Dominique Costagliola
Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(11):1517-26.
2003: Philippe Flandre; Diane Descamps; Véronique Joly; Vincent Meiffrédy; Catherine Tamalet; Jacques Izopet; Jean-Pierre Aboulker; Françoise Brun-Vézinet
Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
Antiviral therapy 2003;8(1):65-72.
2002: Diane Descamps; Philippe Flandre; Véronique Joly; Vincent Meiffrédy; Gilles Peytavin; Jacques Izopet; Catherine Tamalet; Ai-Feng Zeng; Marine Harel; STEPHANE LASTERE; Jean-Pierre Aboulker; Patrick Yéni; Françoise Brun-Vézinet
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
Journal of acquired immune deficiency syndromes (1999) 2002;31(5):464-71.
2002: Véronique Joly; Philippe Flandre; Vincent Meiffredy; Nicolas Leturque; Marine Harel; Jean-Pierre Aboulker; Patrick Yeni
Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.
AIDS (London, England) 2002;16(18):2447-54.
2002: Odile Launay; Laurence Gérard; Laurence Morand-Joubert; Philippe Flandre; Sonia Guiramand-Hugon; Véronique Joly; Gilles Peytavin; Agnès Certain; Claude Lévy; Stéphane Rivet; Christine Jacomet; Jean-Pierre Aboulker; Patrick Yéni
Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;35(9):1096-105.
2002: Véronique Joly; Diane Descamps; Patrick Yeni
NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
AIDS reviews 2002;4(3):128-39.
2002: Véronique Joly; Philippe Flandre; Vincent Meiffredy; Françoise Brun Vezinet; Jean-Albert Gastaut; Cécile Goujard; Gérard Remy; Diane Descamps; Annick Ruffault; Agnès Certain; Jean-Pierre Aboulker; Patrick Yeni
Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
Antimicrobial agents and chemotherapy 2002;46(6):1906-13.
2002: Philippe Flandre; Christine Durier; Diane Descamps; Odile Launay; Véronique Joly
On the use of magnitude of reduction in HIV-1 RNA in clinical trials: statistical analysis and potential biases.
Journal of acquired immune deficiency syndromes (1999) 2002;30(1):59-64.
2002: Pierre Tattevin; Patrick Renault; Véronique Joly; Rui Bastos; Elisabeth Coelho; Christian Adda; Anne Ebel; Patrick Yeni
Treatment of latent syphilis in HIV-infected patients with 10 d of benzylpenicillin G benethamine: a prospective study in Maputo, Mozambique.
Scandinavian journal of infectious diseases 2002;34(4):257-61.
2001: C Auzary; C Pinganaud; Odile Launay; Véronique Joly; A C Cremieux; J M Idatte; C Carbon
[Prosthetic valve endocarditis due to Coxiella burnetii: six cases].
La Revue de médecine interne / fondée ... par la Société nationale francaise de médecine interne 2001;22(10):948-58.
2001: Allan J Hance; V Lemiale; J Izopet; Denise Lecossier; Véronique Joly; P Massip; Fabrizio Mammano; Diane Descamps; Françoise Brun-Vézinet; François Clavel
Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.
Journal of virology 2001;75(14):6410-7.
2001: Sophie Abgrall; I Charreau; Véronique Joly; J Bloch; J Reynes
Risk factors for esophageal candidiasis in a large cohort of HIV-infected patients treated with nucleoside analogues.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2001;20(5):346-9.
2000: Véronique Joly; M Moroni; E Concia; A Lazzarin; Bernard Hirschel; J Jost; F Chiodo; Z Bentwich; W C Love; D A Hawkins; E G Wilkins; A J Gatell; N Vetter; C Greenwald; W W Freimuth; W de Cian
Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group.
Antimicrobial agents and chemotherapy 2000;44(11):3155-7.
2000: K Chemlal; D Nochy; S Kenouch; Véronique Joly; C Carbon
Dramatic improvement of renal dysfunction in a human immunodeficiency virus-infected woman treated with highly active antiretroviral therapy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;31(3):805-6.
2000: Véronique Joly; Patrick Yeni
[Non-nucleoside reverse transcriptase inhibitors].
Annales de médecine interne 2000;151(4):260-7.
1999: Véronique Joly; Patrick Yeni
[Treatment strategies and surveillance of chronic HIV infection in adults].
La Revue du praticien 1999;49(16):1773-80.
1999: A M Been-Tiktak; Charles A B Boucher; Françoise Brun Vezinet; Véronique Joly; J W Mulder; J Jost; D A Cooper; M Moroni; J M Gatell; S Staszewski; Robert Colebunders; G J Stewart; D A Hawkins; M A Johnson; J M Parkin; D H Kennedy; J F Hoy; Jan C C Borleffs
Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial.
International journal of antimicrobial agents 1999;11(1):13-21.
1998: C Besson; S Stélianides; Nadia Belmatoug; O Silbermann-Hoffman; A Couvelard; Véronique Joly; C Carbon; Bruno Fantin
Multifocal osteonecrosis after chemotherapy in a patient with breast cancer.
The Journal of rheumatology 1998;25(12):2479-80.
1998: C Darras-Joly; Jean-Christophe Lucet; Jean-Pierre Laissy; C Chochillon; Enrique Casalino; Véronique Joly; Sophie Matheron; Elisabeth Bouvet
[Invasive pulmonary aspergillosis in AIDS].
Pathologie-biologie 1998;46(6):416-7.
1997: Véronique Joly; Nadia Belmatoug; A Leperre; J Robert; F Jault; C Carbon; Patrick Yeni
Pacemaker endocarditis due to Candida albicans: case report and review.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;25(6):1359-62.
1997: Véronique Joly; Patrick Yeni
[Mono- ad polychemotherapy in HIV infection].
La Revue du praticien 1997;47(4):357-60.
1997: Sophie Abgrall; Véronique Joly; P Derkinderen; Dominique Decré; C Carbon; Patrick Yeni
Lactobacillus casei infection in an AIDS patient.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1997;16(2):180-2.
1997: Véronique Joly
[Prevention of infections in immunosuppressed patients: prevention of post-transfusion infections].
Annales de médecine interne 1997;148(3):268-71.
1997: M L Seux-Levieil; Véronique Joly; Patrick Yeni; C Carbon; F Blanchet
Evaluation of renal acidification in HIV-infected patients with hypergammaglobulinemia.
Nephron 1997;75(2):196-200.
1996: Véronique Joly; P Aubry; A Ndayiragide; I Carrière; E Kawa; N Mlika-Cabanne; Jean-Pierre Aboulker; J P Coulaud; Bernard Larouze; Patrick Yeni
Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;23(3):556-62.
1996: Véronique Joly; Nadia Belmatoug; A Sibert; Claude Carbon; Patrick Yeni
Septic thrombophlebitis of the portal vein.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;23(2):417-8.
1996: C Darras-Joly; S Chevret; Michel Wolff; Sophie Matheron; Pascale Longuet; Enrique Casalino; Véronique Joly; C Chochillon; Jean-Pierre Bédos
Cryptococcus neoformans infection in France: epidemiologic features of and early prognostic parameters for 76 patients who were infected with human immunodeficiency virus.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;23(2):369-76.
1996: Véronique Joly; C Geoffray; J Reynes; C Goujard; D Méchali; C Maslo; F Raffi; Patrick Yeni
Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients.
The Journal of antimicrobial chemotherapy 1996;38(1):117-26.
1996: Bruno Fantin; Véronique Joly; C Elbim; J L Golmard; M A Gougerot-Pocidalo; Patrick Yeni; Claude Carbon
Lymphocyte subset counts during the course of community-acquired pneumonia: evolution according to age, human immunodeficiency virus status, and etiologic microorganisms.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;22(6):1096-8.
1996: Kadoudja Chemlal; L Saint-Julien; Véronique Joly; Robert Farinotti; Nathalie Seta; Patrick Yeni; Claude Carbon
Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits.
Antimicrobial agents and chemotherapy 1996;40(1):263-6.
1995: Véronique Joly; Patrick Yeni
[Treatment of HIV infection with nucleoside analogs: present status].
Presse médicale (Paris, France : 1983) 1995;24(2):103-10.
1994: Véronique Joly; L Saint-Julien; Claude Carbon; Patrick Yeni
In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis.
The Journal of infectious diseases 1994;170(5):1331-4.
1994: P Chavanet; Véronique Joly; D Rigaud; Jacques Bolard; Claude Carbon; Patrick Yeni
Influence of diet on experimental toxicity of amphotericin B deoxycholate.
Antimicrobial agents and chemotherapy 1994;38(5):963-8.
1994: Véronique Joly; Robert Farinotti; L Saint-Julien; Monique Chéron; Claude Carbon; Patrick Yeni
In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid.
Antimicrobial agents and chemotherapy 1994;38(2):177-83.
1993: Véronique Joly; Patrick Yeni
[Vectorization of drugs. A winsome concept with delicate practical applications].
La Revue du praticien 1993;43(16):2100-3.
1992: L Saint-Julien; Véronique Joly; M Seman; Claude Carbon; Patrick Yeni
Activity of MS-8209, a nonester amphotericin B derivative, in treatment of experimental systemic mycoses.
Antimicrobial agents and chemotherapy 1992;36(12):2722-8.
1992: Véronique Joly; Jacques Bolard; Patrick Yeni
In vitro models for studying toxicity of antifungal agents.
Antimicrobial agents and chemotherapy 1992;36(9):1799-804.
1992: Odile Eloy; Véronique Joly; Jean-Claude Ghnassia; C Carbon; Patrick Yeni
[Choice and monitoring of the treatment of systemic mycoses. Value and limitations of in vitro tests].
Presse médicale (Paris, France : 1983) 1992;21(20):937-42.
1992: Véronique Joly; M Saint-Pierre-Chazalet; L Saint-Julien; Jacques Bolard; Claude Carbon; Patrick Yeni
Inhibiting cholesterol synthesis reduces the binding and toxicity of amphotericin B against rabbit renal tubular cells in primary culture.
The Journal of infectious diseases 1992;165(2):337-43.
1992: Véronique Joly; Jacques Bolard; L Saint-Julien; Claude Carbon; Patrick Yeni
Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations.
Antimicrobial agents and chemotherapy 1992;36(2):262-6.
1992: P Le Conte; Véronique Joly; L Saint-Julien; J M Gillardin; Claude Carbon; Patrick Yeni
Tissue distribution and antifungal effect of liposomal itraconazole in experimental cryptococcosis and pulmonary aspergillosis.
The American review of respiratory disease 1992;145(2 Pt 1):424-9.
1991: Pascale Longuet; Véronique Joly; P Amirault; Nathalie Seta; Claude Carbon; Patrick Yeni
Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in rats.
Antimicrobial agents and chemotherapy 1991;35(7):1303-8.
1991: C Pierre; Denise Lecossier; Y Boussougant; D Bocart; Véronique Joly; Patrick Yeni; Allan J Hance
Use of a reamplification protocol improves sensitivity of detection of Mycobacterium tuberculosis in clinical samples by amplification of DNA.
Journal of clinical microbiology 1991;29(4):712-7.
1991: Véronique Joly; Y Bergeron; M G Bergeron; Claude Carbon
Endotoxin-tobramycin additive toxicity on renal proximal tubular cells in culture.
Antimicrobial agents and chemotherapy 1991;35(2):351-7.
1990: Véronique Joly; L Saint-Julien; Claude Carbon; Patrick Yeni
Interactions of free and liposomal amphotericin B with renal proximal tubular cells in primary culture.
The Journal of pharmacology and experimental therapeutics 1990;255(1):17-22.
1990: L Pisarik; Véronique Joly; S Jullien; C Carbon; Patrick Yeni
Reduction of free amphotericin B acute toxicity in mice after intravenous administration of empty liposomes.
The Journal of infectious diseases 1990;161(5):1042-4.
1989: Véronique Joly; Patrick Yeni
[Liposomes].
Presse médicale (Paris, France : 1983) 1989;18(40):1957-9.
1989: Véronique Joly; F Dromer; J Barge; Patrick Yeni; Nathalie Seta; G Molas; Claude Carbon
Incorporation of amphotericin B (AMB) into liposomes alters AMB-induced acute nephrotoxicity in rabbits.
The Journal of pharmacology and experimental therapeutics 1989;251(1):311-6.
1988: Véronique Joly; Béatrice Pangon; N Brion; J M Vallois; Claude Carbon
Enhancement of the therapeutic effect of cephalosporins in experimental endocarditis by altering their pharmacokinetics with diclofenac.
The Journal of pharmacology and experimental therapeutics 1988;246(2):695-700.
1988: A Contrepois; Véronique Joly; L Abel; Béatrice Pangon; J M Vallois; C Carbon
The pharmacokinetics and extravascular diffusion of teicoplanin in rabbits and comparative efficacy with vancomycin in an experimental endocarditis model.
The Journal of antimicrobial chemotherapy 1988;21(5):621-31.
1987: Véronique Joly; Béatrice Pangon; J M Vallois; L Abel; N Brion; A Bure; NGUYEN PHONG CHAU; A Contrepois; Claude Carbon
Value of antibiotic levels in serum and cardiac vegetations for predicting antibacterial effect of ceftriaxone in experimental Escherichia coli endocarditis.
Antimicrobial agents and chemotherapy 1987;31(10):1632-9.
1987: P Chanson; Véronique Joly; A Contrepois; J J Garaud; J Bauchet; J Mohler; P C Nguyen; Claude Carbon
Alteration of gentamicin and cefazolin kinetics with control of the hypothyroid state in humans.
Antimicrobial agents and chemotherapy 1987;31(4):635-7.
1987: Béatrice Pangon; Véronique Joly; J M Vallois; L Abel; A Buré; N Brion; A Contrepois; Claude Carbon
Comparative efficacy of cefotiam, cefmenoxime, and ceftriaxone in experimental endocarditis and correlation with pharmacokinetics and in vitro efficacy.
Antimicrobial agents and chemotherapy 1987;31(4):518-22.
1986: N Brion; Véronique Joly; D Champetier de Ribes; F Meier; F Courtois; C Carbon
[Is systematic syphilis serology still useful in a department of internal medicine? A one-year prospective study using a diagnostic and therapeutic decision algorithm].
Presse médicale (Paris, France : 1983) 1986;15(37):1851-4.